JP7239575B2 - サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 - Google Patents

サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 Download PDF

Info

Publication number
JP7239575B2
JP7239575B2 JP2020522785A JP2020522785A JP7239575B2 JP 7239575 B2 JP7239575 B2 JP 7239575B2 JP 2020522785 A JP2020522785 A JP 2020522785A JP 2020522785 A JP2020522785 A JP 2020522785A JP 7239575 B2 JP7239575 B2 JP 7239575B2
Authority
JP
Japan
Prior art keywords
autonomously
cells
cell
seq
bcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020522785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527727A (ja
JP2020527727A5 (https=
Inventor
ビアスナー ウルリヒ
ユマー ハッサン
クラップロート ホルガー
アー． ケセマイアー マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVA Lifescience GmbH
Original Assignee
AVA Lifescience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVA Lifescience GmbH filed Critical AVA Lifescience GmbH
Publication of JP2020527727A publication Critical patent/JP2020527727A/ja
Publication of JP2020527727A5 publication Critical patent/JP2020527727A5/ja
Application granted granted Critical
Publication of JP7239575B2 publication Critical patent/JP7239575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020522785A 2017-07-07 2018-07-05 サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 Active JP7239575B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17001166.2 2017-07-07
EP17001167 2017-07-07
EP17001167.0 2017-07-07
EP17001166 2017-07-07
EP18162666.4A EP3424527A1 (de) 2017-07-07 2018-03-19 Diagnostisches verfahren
EP18162666.4 2018-03-19
PCT/EP2018/068316 WO2019008128A1 (de) 2017-07-07 2018-07-05 Diagnostisches verfahren

Publications (3)

Publication Number Publication Date
JP2020527727A JP2020527727A (ja) 2020-09-10
JP2020527727A5 JP2020527727A5 (https=) 2021-08-12
JP7239575B2 true JP7239575B2 (ja) 2023-03-14

Family

ID=64500047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020522785A Active JP7239575B2 (ja) 2017-07-07 2018-07-05 サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法
JP2020522786A Active JP7271532B2 (ja) 2017-07-07 2018-07-05 生物学的結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020522786A Active JP7271532B2 (ja) 2017-07-07 2018-07-05 生物学的結合分子

Country Status (5)

Country Link
US (2) US11634487B2 (https=)
EP (4) EP3424527A1 (https=)
JP (2) JP7239575B2 (https=)
CA (1) CA3070848A1 (https=)
WO (2) WO2019008128A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424527A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren
EP3733709A1 (de) * 2019-05-02 2020-11-04 AVA Lifescience Biologische bindemoleküle
CA3148214A1 (en) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Antigent binding domains and uses therefor
WO2020221463A1 (de) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle
IL310901A (en) * 2021-08-18 2024-04-01 Univ Pennsylvania Compositions and methods for chimeric antigen receptors specific to b cell receptors
EP4227321A1 (en) * 2022-02-10 2023-08-16 AVA Lifescience GmbH Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
EP4476264A1 (en) 2022-02-10 2024-12-18 SinABioSolution GmbH Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
CA3262006A1 (en) * 2022-07-25 2024-02-01 Sinabiosolution Gmbh Humanized chimeric antigen receptors targeting the B-lymphocyte receptor in chronic lymphocytic leukemia and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526590A (ja) 2017-07-07 2020-08-31 アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハーＡＶＡ Ｌｉｆｅｓｃｉｅｎｃｅ ＧｍｂＨ 生物学的結合分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP3539985A1 (en) * 2012-02-24 2019-09-18 AbbVie Stemcentrx LLC Anti sez6 antibodies and methods of use
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
SG11201601424PA (en) * 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526590A (ja) 2017-07-07 2020-08-31 アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハーＡＶＡ Ｌｉｆｅｓｃｉｅｎｃｅ ＧｍｂＨ 生物学的結合分子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOJARCZUK, K. et al.，B-cell receptor signaling in the pathogenesis of lymphoid malignancies，Blood Cells, Molecules and Diseases，2015年，Vol.55，pp.255-265
MINDEN, M. D. et al.，Chronic lymphocyic leukaemia is driven by antigen-independent cell-autonomous signalling，Nature，2012年09月13日，Vol.489，pp.309-312
MINICI, C. et al.，Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia，nature communications，2017年06月09日，Vol.8, Article number: 15746，pp.1-12

Also Published As

Publication number Publication date
US20200199225A1 (en) 2020-06-25
US11634487B2 (en) 2023-04-25
EP3424527A1 (de) 2019-01-09
JP2020526590A (ja) 2020-08-31
EP3424528A1 (de) 2019-01-09
WO2019008128A1 (de) 2019-01-10
JP2020527727A (ja) 2020-09-10
EP3615072A1 (de) 2020-03-04
US20200209246A1 (en) 2020-07-02
JP7271532B2 (ja) 2023-05-11
WO2019008129A1 (de) 2019-01-10
US11591391B2 (en) 2023-02-28
CA3070847A1 (en) 2019-01-10
CA3070848A1 (en) 2019-01-10
EP3615073A1 (de) 2020-03-04

Similar Documents

Publication Publication Date Title
JP7239575B2 (ja) サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法
JP2022515318A (ja) 抗体及びその用途
US20190077872A1 (en) Method for enhancing humoral immune response
JP7796160B2 (ja) 生物学的結合分子
US20240141038A1 (en) Antibody against nkp46 and application thereof
CN113260861A (zh) 用于选择生物结合分子的方法
KR102427948B1 (ko) 다발성 골수종에서 m-단백질 반응의 임상 평가
Masuko et al. Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein
JP7082112B2 (ja) 抗ｇｐｒ２０抗体
CA3070847C (en) Diagnostic method
CN114364698B (zh) 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
US20230393144A1 (en) Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assays
WO2021147954A1 (zh) Semg2抗体及其用途
CA3140488C (en) Method for selecting biological binding molecules
US20240329048A1 (en) Antibodies targeting intracellular tumor antigens and methods for identifying both
US20220356244A1 (en) Method for selecting biological binding molecules
WO2025061149A1 (zh) 抗gcc抗体、嵌合抗原受体及其用途
WO2026020409A1 (zh) uPAR抗体及其应用
WO2024165500A1 (en) Vhh-based nkp46 binders
HK1228954A1 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230302

R150 Certificate of patent or registration of utility model

Ref document number: 7239575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250